| 101 |
16553572 | The pharmacological treatment of primary aldosteronism. | 2006 Apr |
1 |
| 102 |
16611048 | Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard? | 2006 Apr |
1 |
| 103 |
16754797 | Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. | 2006 Jul |
1 |
| 104 |
16877339 | MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. | 2006 Aug |
1 |
| 105 |
17075718 | Why are mineralocorticoid receptor antagonists cardioprotective? | 2006 Dec |
2 |
| 106 |
19804189 | Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. | 2006 Sep |
1 |
| 107 |
15590870 | Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. | 2005 Jan |
2 |
| 108 |
15733814 | The aldosterone antagonist and facultative diuretic eplerenone: a critical review. | 2005 Feb |
1 |
| 109 |
15761029 | The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. | 2005 Jun |
1 |
| 110 |
15860254 | RALES, EPHESUS and redox. | 2005 Feb |
2 |
| 111 |
16101407 | Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. | 2005 Aug |
4 |
| 112 |
16342656 | Aldosterone receptor antagonists in the medical management of chronic heart failure. | 2005 Dec |
1 |
| 113 |
16366159 | Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. | 2005 Nov-Dec |
1 |
| 114 |
15128471 | Aldosterone and aldosterone antagonism in systemic hypertension. | 2004 Jun |
1 |
| 115 |
15160833 | Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. | 2004 May 1 |
1 |
| 116 |
15181050 | Distinguishing the antihypertensive and electrolyte effects of eplerenone. | 2004 Jun |
1 |
| 117 |
15182600 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? | 2004 Jul |
2 |
| 118 |
15257862 | Mineralocorticoid receptor antagonists and hypertension: is there a rationale? | 2004 Aug |
2 |
| 119 |
15349128 | Eplerenone: a new selective aldosterone receptor antagonist. | 2004 Jun |
2 |
| 120 |
15554912 | Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. | 2004 Oct |
14 |
| 121 |
16036025 | Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms. | 2004 Jul |
1 |
| 122 |
16200104 | Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. | 2004 Apr |
2 |
| 123 |
12624573 | Aldosterone receptor antagonists: focus on eplerenone. | 2003 Winter |
2 |
| 124 |
12914736 | Primary aldosteronism - treatment options. | 2003 Aug |
1 |
| 125 |
12962513 | Aldosterone receptor antagonists for hypertension: what do they offer? | 2003 |
1 |
| 126 |
14640940 | The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. | 2003 Dec |
3 |
| 127 |
12431020 | The role of aldosterone receptor blockade in the management of cardiovascular disease. | 2002 Oct |
2 |
| 128 |
12555163 | Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? | 2002 Dec |
1 |
| 129 |
10760075 | Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. | 2000 Apr |
3 |